semaglutide cardiovascular trial New Science Suggests Improves CV Outcomes Beyond Weight Loss Long-Term SELECT Trial: Semaglutide Cuts
Description
Dulaglutide (Trulicity) is another GLP-1 receptor agonist, but is licensed only for type 2 diabetes in the UK, not for weight management
however, severe or persistent gastrointestinal symptoms may warrant dose slowing or medication adjustment
Effects of semaglutide on Alzheimers disease-related biological processes: results from a biofluid biomarker and multiomics immunophenotyping phase 3 Study in patients with early Alzheimers disease after 12 weeks of treatment
The stomach stuff in the first few weeks was manageable
Our platform connects you with licensed providers who look at your entire health profile, including your current use of medications like methotrexate
doi: 10.1186/s13045-023-01430-8
